Medicis reveals purchase price
This article was originally published in The Gray Sheet
Executive Summary
Thanks to the close of the Allergan/Inamed deal, Medicis' exclusive license of Ipsen's Reloxin botulinum toxin type A product goes through for $90.1 mil. in cash, plus nearly $103 mil. in milestone payments. Ipsen will manufacture the product and Medicis will have the right to develop and distribute the product exclusively until 2019. Inamed previously had rights to the product but divested them in order to avoid antitrust snags due to Allergan's existing Botox product (1"The Gray Sheet" March 20, 2006, p. 17)...